Table 1.
Baseline characteristics of rheumatoid arthritis patients at study entry
| Patients | Responder | Nonresponder | P value |
|---|---|---|---|
| Number of patients | 31 | 19 | |
| Sex (male:female) | 7:24 | 4:15 | 0.61 |
| Mean (range) age (years) | 55.8 (41 to 75) | 55.9 (40 to 71) | 0.97 |
| Cardiovascular risk factors (≥1, % positive) | 51.1 | 65.4 | 0.12 |
| IgM-RF (% positive) | 54.8 | 31.6 | 0.17 |
| Anti-CCP (% positive) | 64.5 | 31.6 | 0.15 |
| Mean (standard deviation) DAS28 | 4.82 (±1.19) | 5.30 (±1.55) | 0.22 |
| Mean (range) CRP (mg/l) | 10.9 (2.0 to 114.5) | 11.4 (2.0 to 80.7) | 0.93 |
| Mean (range) disease duration (years) | 6.92 (2 to 29) | 5.4 (1 to 19) | 0.84 |
| Therapy | |||
| Corticosteroids | 23 | 11 | |
| DMARDs | |||
| Methotrexate | 24 | 15 | |
| Leflunomide | 7 | 4 |
Anti-CCP, anti-cyclic citrullinated peptide antibodies; CRP, C-reactive protein; DAS28, Disease activity score in 28 joints at study visit V1; DMARD, disease-modifying antirheumatic drug; RF, rheumatoid factor.